Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 8:47 PM View:  | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 03-Apr-24 | Sale (Planned) | 138,066 | $6.20 | $856,009.00 | (2%) 6.38M to 6.24M | |
| 03-Apr-24 8:47 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 02-Apr-24 | Sale (Planned) | 101,480 | $6.65 | $674,842.00 | (2%) 6.48M to 6.38M | |
| 03-Apr-24 8:47 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 01-Apr-24 | Private Sale (Planned) | 181,117 | $6.99 | $1,266,010.00 | (3%) 6.66M to 6.48M | |
| 25-Jan-24 7:17 PM View: | Quirk Erin President, Head of R&D | Terns Pharmaceuticals, Inc. (TERN) | 23-Jan-24 | Grant | 75,000 | -- | -- | 100% 0 to 75.0K | |
| 25-Jan-24 7:18 PM View: | Quigley Jill M. Sr. Advisor & Strategy Officer Director | Terns Pharmaceuticals, Inc. (TERN) | 23-Jan-24 | Grant | 15,000 | -- | -- | 100% 15.0K to 30.0K | |
| 25-Jan-24 7:17 PM View: | Vignola Mark J. Chief Financial Officer | Terns Pharmaceuticals, Inc. (TERN) | 23-Jan-24 | Grant | 68,750 | -- | -- | 374% 18.4K to 87.15K | |
| 25-Jan-24 7:18 PM View: | Yoon Seokho Bryan COO and General Counsel | Terns Pharmaceuticals, Inc. (TERN) | 23-Jan-24 | Grant | 68,750 | -- | -- | 374% 18.4K to 87.15K | |
| 04-Dec-23 6:03 PM View: | Vignola Mark J. Chief Financial Officer | Terns Pharmaceuticals, Inc. (TERN) | 30-Nov-23 | Private Purchase | 743 | $3.78 | $2,808.54 | 4% 17.66K to 18.4K | |
| 04-Dec-23 6:03 PM View: | Yoon Seokho Bryan COO and General Counsel | Terns Pharmaceuticals, Inc. (TERN) | 30-Nov-23 | Private Purchase | 743 | $3.78 | $2,808.54 | 4% 17.66K to 18.4K | |
| 17-Nov-23 6:10 PM View: | Quigley Jill M. Sr. Advisor & Strategy Officer Director | Terns Pharmaceuticals, Inc. (TERN) | 15-Nov-23 | Grant | 15,000 | -- | -- | 100% 0 to 15.0K | |
| 02-Jun-23 5:03 PM View: | Sundaram Senthil Vel Chief Executive Officer Director | Terns Pharmaceuticals, Inc. (TERN) | 31-May-23 | Private Purchase | 2,111 | $1.41 | $2,976.51 | 28% 7.66K to 9.77K | |
| 02-Jun-23 5:03 PM View: | Yoon Seokho Bryan COO and General Counsel | Terns Pharmaceuticals, Inc. (TERN) | 31-May-23 | Private Purchase | 9,997 | $1.41 | $14,095.80 | 131% 7.66K to 17.66K | |
| 02-Jun-23 5:03 PM View: | Vignola Mark J. Chief Financial Officer | Terns Pharmaceuticals, Inc. (TERN) | 31-May-23 | Private Purchase | 9,997 | $1.41 | $14,095.80 | 131% 7.66K to 17.66K | |
| 28-Dec-22 5:46 PM View: | Gordon Carl L Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 23-Dec-22 | Purchase | 137,931 | $7.25 | $1,000,000.00 | 2% 7.48M to 7.62M | |
| 23-Dec-22 5:44 PM View: | Lu Hongbo Director | Terns Pharmaceuticals, Inc. (TERN) | 23-Dec-22 | Purchase | 758,620 | $7.25 | $5,500,000.00 | 21% 3.58M to 4.34M | |
| 28-Dec-22 5:57 PM View: | Orbimed Advisors LLC Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 23-Dec-22 | Purchase Duplicate | 137,931 | $7.25 | $1,000,000.00 | 2% 7.48M to 7.62M | |
| 23-Dec-22 5:48 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 23-Dec-22 | Purchase Duplicate | 758,620 | $7.25 | $5,500,000.00 | 13% 5.9M to 6.66M | |
| 03-Feb-23 6:01 PM View: | Yoon Seokho Bryan COO and General Counsel | Terns Pharmaceuticals, Inc. (TERN) | 30-Nov-22 | Private Purchase | 3 | $1.41 | $4.23 | < 1% 7.66K to 7.66K | |
| 03-Feb-23 6:00 PM View: | Sundaram Senthil Vel Chief Executive Officer Director | Terns Pharmaceuticals, Inc. (TERN) | 30-Nov-22 | Private Purchase | 3 | $1.41 | $4.23 | < 1% 7.66K to 7.66K | |
| 03-Feb-23 6:01 PM View: | Vignola Mark J. Chief Financial Officer | Terns Pharmaceuticals, Inc. (TERN) | 30-Nov-22 | Private Purchase | 3 | $1.41 | $4.23 | < 1% 7.66K to 7.66K | |
| 28-Nov-22 4:56 PM View: | Lav Biosciences Fund V, L.P. 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 23-Nov-22 | Market Sale | 1,500,000 | $5.50 | $8,250,000.00 | (31%) 4.78M to 3.28M | (15%) |
| 08-Sep-22 8:00 PM View: | Lu Hongbo Director | Terns Pharmaceuticals, Inc. (TERN) | 07-Sep-22 | Private Purchase | 600,000 | $3.60 | $2,160,000.00 | 20% 2.98M to 3.58M | |
| 08-Sep-22 8:00 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 07-Sep-22 | Private Purchase Duplicate | 600,000 | $3.60 | $2,160,000.00 | 11% 5.3M to 5.9M | |
| 16-Aug-22 8:30 PM View: | Lu Hongbo Director | Terns Pharmaceuticals, Inc. (TERN) | 16-Aug-22 | Purchase | 1,500,000 | $2.42 | $3,630,000.00 | 101% 1.48M to 2.98M | |
| 18-Aug-22 5:00 PM View: | Orbimed Advisors LLC Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 16-Aug-22 | Private Purchase Duplicate | 3,690,000 | $2.42 | $8,929,800.00 | 97% 3.79M to 7.48M | |
| 16-Aug-22 8:44 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 16-Aug-22 | Purchase Duplicate | 1,500,000 | $2.42 | $3,630,000.00 | 28% 5.28M to 6.78M | |
| 18-Aug-22 4:50 PM View: | Gordon Carl L Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 16-Aug-22 | Private Purchase | 3,690,000 | $2.42 | $8,929,800.00 | 97% 3.79M to 7.48M | |
| 16-Aug-22 8:30 PM View: | Lu Hongbo Director | Terns Pharmaceuticals, Inc. (TERN) | 15-Aug-22 | Purchase | 1,218 | $2.99 | $3,641.82 | < 1% 1.48M to 1.48M | |
| 16-Aug-22 8:44 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 15-Aug-22 | Purchase Duplicate | 1,218 | $2.99 | $3,641.82 | < 1% 5.28M to 5.28M | |
| 16-Aug-22 8:44 PM View: | Vivo Opportunity, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 12-Aug-22 | Private Purchase Duplicate | 1,123,020 | $2.98 | $3,346,600.00 | 27% 4.16M to 5.28M | |
| 16-Aug-22 8:30 PM View: | Lu Hongbo Director | Terns Pharmaceuticals, Inc. (TERN) | 12-Aug-22 | Private Purchase | 1,123,020 | $2.98 | $3,346,600.00 | 314% 357.35K to 1.48M | |
| 08-Jun-22 9:27 PM View: | Vignola Mark J. Chief Financial Officer | Terns Pharmaceuticals, Inc. (TERN) | 31-May-22 | Private Purchase | 7,656 | $1.47 | $11,254.30 | 100% 0 to 7.66K | |
| 08-Jun-22 9:28 PM View: | Yoon Seokho Bryan COO and General Counsel | Terns Pharmaceuticals, Inc. (TERN) | 31-May-22 | Private Purchase | 7,656 | $1.47 | $11,254.30 | 100% 0 to 7.66K | |
| 08-Jun-22 9:27 PM View: | Sundaram Senthil Vel Chief Executive Officer Director | Terns Pharmaceuticals, Inc. (TERN) | 31-May-22 | Private Purchase | 7,656 | $1.47 | $11,254.30 | 100% 0 to 7.66K | |
| 09-Feb-21 3:08 PM View: | Vivo Capital Viii, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Conversion | 2,200,130 | -- | -- | 100% 0 to 2.2M | |
| 09-Feb-21 5:00 PM View: | Lav Biosciences Fund V, L.P. 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Conversion | 4,781,570 | -- | -- | 100% 0 to 4.78M | |
| 09-Feb-21 3:09 PM View: | Orbimed Advisors LLC Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Purchase Duplicate | 475,000 | $17.00 | $8,075,000.00 | 14% 3.32M to 3.79M | |
| 09-Feb-21 3:09 PM View: | Orbimed Advisors LLC Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Conversion | 3,316,200 | -- | -- | 100% 0 to 3.32M | |
| 09-Feb-21 2:55 PM View: | Flynn James E 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Purchase | 665,000 | $17.00 | $11,305,000.00 | 39% 1.72M to 2.38M | |
| 09-Feb-21 3:10 PM View: | Gordon Carl L Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Purchase Duplicate | 475,000 | $17.00 | $8,075,000.00 | 14% 3.32M to 3.79M | |
| 09-Feb-21 2:55 PM View: | Flynn James E 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Conversion | 1,717,030 | -- | -- | 100% 0 to 1.72M | |
| 09-Feb-21 3:10 PM View: | Gordon Carl L Director 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Conversion Duplicate | 3,316,200 | -- | -- | 100% 0 to 3.32M | |
| 09-Feb-21 3:08 PM View: | Vivo Capital Viii, LLC 10% Owner | Terns Pharmaceuticals, Inc. (TERN) | 09-Feb-21 | Purchase | 475,000 | $17.00 | $8,075,000.00 | 22% 2.2M to 2.68M |
